Search clinical trials for: Vericiguat (BAY1021189)

Total 32 results

Bayer
Merck Sharp & Dohme LLC

Completed

A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately

Heart Failure | Children

Germany
Bayer

Completed

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

Heart Failure

Belgium, France, Switzerland, United States, Spain, Greece, Japan, Singapore, Austria, Germany, Korea, Republic of, Poland, Denmark, Israel, Netherlands, Taiwan, Bulgaria, Canada, Sweden, Czechia, Australia, Italy, Hungary, United Kingdom
Bayer

Completed

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

Heart Failure

Belgium, France, Spain, Greece, Portugal, Japan, United States, Singapore, Austria, Germany, Korea, Republic of, Poland, Australia, Israel, Netherlands, Switzerland, Taiwan, Bulgaria, Canada, Czechia, Denmark, Hungary, Italy, Sweden, United...
Bayer

Active, not recruiting

An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States (HOVER)

Chronic Heart Failure With Reduced Ejection Fraction

United States
Bayer

Recruiting

An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting

Chronic Heart Failure With Reduced Ejection Fraction

Korea, Republic of
Bayer

Recruiting

A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)

Chronic Heart Failure With Reduced Ejection Fraction | Worsening Heart Failure

India
Bayer
Merck Sharp & Dohme LLC

Not yet recruiting

A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Chronic Heart Failure With Reduced Ejection Fraction

Spain, Italy, United States, Sweden, Poland, Argentina, Hungary
Bayer

Recruiting

A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions

Chronic Heart Failure

Japan
Bayer

Recruiting

An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China (VERI-China)

Chronic Heart Failure With Reduced Ejection Fraction

China
Bayer
Merck Sharp & Dohme LLC

Completed

A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants

Heart Failure

Germany
Bayer

Completed

Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects

Pharmacokinetics

Germany
Bayer
Merck Sharp & Dohme LLC

Completed

A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants

Heart Failure

Germany
Bayer
Merck Sharp & Dohme LLC

Completed

Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients (VENICE)

Coronary Artery Disease

Germany
Bayer
Merck Sharp & Dohme LLC; Duke Clinical Research Institute; Canadian VIGOUR Centre

Completed

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF (VITALITY-HFpEF)

Chronic Heart Failure With Preserved Ejection Fraction

Spain, United States, Belgium, Singapore, Taiwan, Canada, Japan, Italy, Austria, Bulgaria, Germany, Greece, Israel, Poland, Portugal, Hungary, Russian Federation, Argentina, Colombia, Malaysia, South Africa
Merck Sharp & Dohme LLC
Bayer; Duke Clinical Research Institute; Canadian VIGOUR Centre

Completed

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) (VICTORIA)

Heart Failure | Chronic Heart Failure With Reduced Ejection Fraction
Bayer
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat

Coronary Artery Disease

Germany, Moldova, Republic of, Netherlands
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Effect of Vericiguat on Endpoint Events in Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45%

Acute Coronary Syndrome | Heart Failure With Reduced Ejection Fraction

China
University of Colorado, Denver

Not yet recruiting

Impact of Vericiguat on Hemodynamics of Heart Failure

Heart Failure
Vanderbilt University Medical Center
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery (SOLSTICE)

Vascular Diseases | Endothelial Dysfunction | Kidney Injury | Brain Disease | Vascular Inflammation

United States
Johns Hopkins University
Merck Sharp & Dohme LLC

Recruiting

Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction

Metabolic Syndrome | Coronary Microvascular Dysfunction

United States
Charite University, Berlin, Germany
Bayer

Not yet recruiting

Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome

Post-COVID ME/CFS

Germany
Merck Sharp & Dohme LLC

Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Heart Failure | Left Ventricular Systolic Dysfunction

Korea, Republic of, United States, France, Finland, Portugal, Sweden, Denmark, Spain, Turkey, Hungary, Netherlands, Ireland, Malaysia, Colombia, Germany, Singapore, Thailand, Italy, New Zealand, Belgium, Brazil, Canada, United Kingdom
Bayer
Merck Sharp & Dohme LLC

Completed

Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients (VISOR)

Coronary Artery Disease

Germany
Josef Stehlik
Merck Sharp & Dohme LLC

Recruiting

The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation

Heart Failure | Heart Failure With Reduced Ejection Fraction (HFrEF)

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) (VICTOR)

Chronic Heart Failure With Reduced Ejection Fraction

China, United States, Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Malaysia, Mexico, New Zealand, Peru and more
The University of Hong Kong

Not yet recruiting

Randomised Controlled Trial of Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)

Chest Pain

Hong Kong
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Recruiting

A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction

Breast Cancer | Cardiac Dysfunction

United States
University of Alabama at Birmingham

Not yet recruiting

VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway (VITAL-IMPACT)

Cardiovascular Diseases | Obesity | Insulin Sensitivity/Resistance | Metabolic Disease | Energy Expenditure | Metabolism

United States
University of Giessen
Philipps University Marburg Medical Center

Recruiting

(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment) (RightHeartIII)

Pulmonary Arterial Hypertension (PAH)

Germany
Assistance Publique - Hôpitaux de Paris

Completed

Cluster Headache Cortivazol Injection (CHCI) (CHCI)

Cluster Headache

France
GlaxoSmithKline

Terminated

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Hartford Hospital
Astellas Pharma Inc

Completed

Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging

Myocardial Ischemia | Coronary Artery Disease

United States

3

Subscribe